Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

Prostate cancer and prostatic diseases·2015
Same author

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.

European journal of cancer (Oxford, England : 1990)·2013
Same author

Penile cancer: current therapy and future directions.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.

British journal of cancer·2008
Same author

Review of metastatic bladder cancer.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2006
Same journal

Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.

World journal of urology·2026
Same journal

Intrarenal pressure and clinical outcomes during suction-assisted versus conventional percutaneous nephrolithotomy: a systematic review and meta-analysis.

World journal of urology·2026
Same journal

AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical data.

World journal of urology·2026
Same journal

Comment on "Nurse-led postoperative telemonitoring program following outpatient urethroplasty: a pilot study".

World journal of urology·2026
Same journal

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.

World journal of urology·2026
Same journal

Modified HoLEP technique: does it preserve ejaculation?

World journal of urology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

Gene therapy for bladder cancer.

L C Pagliaro1

  • 1Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. lpagliar@mdanderson.org

World Journal of Urology
|June 15, 2000
PubMed
Summary
This summary is machine-generated.

Gene therapy using adenovirus delivers tumor-suppressor p53 to bladder cancer cells. This approach, tested in a phase I trial, aims to inhibit tumor growth and preserve the bladder.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: May 22, 2026

An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Tumor-suppressor genes are crucial for controlling cell growth.
  • p53 gene mutations are common in bladder cancer, leading to uncontrolled cell proliferation.
  • Adenoviral vectors offer a method for in vivo gene delivery to tumor cells.

Purpose of the Study:

  • To evaluate the safety and efficacy of adenovirus-mediated p53 gene transfer in bladder cancer patients.
  • To assess the potential of Ad5CMV-P53 vector for inhibiting tumor growth.
  • To establish a foundation for future clinical trials integrating gene therapy with standard treatments.

Main Methods:

  • Utilizing a replication-defective adenoviral vector (Ad5CMV-P53) carrying wild-type human p53.
  • Administering the vector intravesically (directly into the bladder).
  • Conducting a phase I clinical trial to assess safety and preliminary efficacy.

Main Results:

  • Adenovirus-mediated p53 gene transfer demonstrated in vitro growth inhibition of bladder cancer cells.
  • Phase I clinical trial initiation for intravesical administration of Ad5CMV-P53.
  • Preliminary data suggests the potential for therapeutic benefit in bladder cancer.

Conclusions:

  • Adenovirus-mediated p53 gene transfer is a promising strategy for bladder cancer treatment.
  • The Ad5CMV-P53 vector shows potential for therapeutic application in vivo.
  • Further clinical trials are warranted to integrate gene therapy for improved bladder cancer outcomes.